Table 1 Patient characteristics

Age, years, median (IQR)

3.0 (1.8–4.8)

3.2 (1.8–4.8)

2.6 (1.6–3.5)

0.033

Male sex, N (%male)

110 (54.2)

76 (58.0)

26 (44.8)

0.093

Asthma control

0.66

Well-controlled, N (%)

59 (29.1)

41 (31.3)

16 (27.6)

Partially controlled, N (%)

72 (35.5)

49 (37.4)

20 (34.5)

Uncontrolled, N (%)

72 (35.5)

41 (31.3)

22 (37.9)

Controller medications

0.25

LTRAs, N (%)

44 (21.7)

31 (23.7)

10 (17.2)

ICSs, N (%)

4 (2.0)

3 (2.3)

0

LTRAs + ICSs, N (%)

30 (14.8)

19 (14.5)

10 (17.2)

ICSs/LABAs, N (%)

1 (0.5)

0

1 (1.7)

LTRAs + ICSs/LABAs, N (%)

12 (5.9)

6 (4.6)

6 (10.3)

LTRAs + ICSs/LABAs + LAMAs + dupilumab, N (%)

1 (0.5)

0

0

None, N (%)

111 (54.7)

72 (55.0)

31 (53.4)

White blood cells/μL, median (IQR)

11,450 (8,700–16,125)

13,850 (10,400–17,475)

7,900 (6,300–11,750)

 < 0.001

Eosinophils/μL, median (IQR)

71 (0–251)

152 (39–299)

0 (0–39)

 < 0.001

Total IgE, IU/mL, median (IQR)

250 (68–808)

334 (129–1,107)

92 (16–390)

 < 0.001

House dust mite-specific IgE, UA/mL, median (IQR)

1.9 (0.01–52.6)

8.6 (0.01–68.5)

0.1 (0.01–16.1)

0.019

Duration of hospitalization, days, median (IQR)

5 (4–6)

4 (4–5)

5 (5–7)

 < 0.001

Duration of oxygen therapy, days, median (IQR)

2 (1–3)

2 (1–3)

3 (2–5)

 < 0.001

Duration of systemic glucocorticoid therapy, days, median (IQR)

3 (2–5)

3 (3–4)

4 (2–5)

0.42

Exacerbation severity

0.62

Mild, N (%)

8 (4.0)

4 (3.1)

3 (5.1)

Moderate, N (%)

167 (82.3)

111 (84.7)

46 (79.3)

Severe, N (%)

28 (13.8)

16 (12.2)

9 (15.5)